NZ554213A

NZ554213A - Modified release ibuprofen dosage form

Info

Publication number: NZ554213A
Application number: NZ554213A
Authority: NZ
Inventors: Michael Hite; Cathy Federici; Alan Brunelle; Stephen Turner
Original assignee: Scolar Pharma Inc
Priority date: 2004-09-30
Filing date: 2005-09-30
Publication date: 2010-01-29
Also published as: HK1107002A1; AU2005292185A1; EP1793809B1; BRPI0516718B1; WO2006039692A3; AU2005292185B2; EP1793809A4; WO2006039692A2; MX2007003919A; IL182144A0; US20060068009A1; BRPI0516718A; EP1793809A2; PL1793809T3; BRPI0516718B8; KR20070064352A; CA2582150C; CA2582150A1; JP2008515802A; IL182144A

Abstract

The disclosure relates to a solid dosage form for modified oral administration of ibuprofen comprising: i) a hydrophilic polymer; ii) 300 to 800 mg of ibuprofen in the solid dosage form uniformly dispersed in said polymer; iii) a dissolution additive dispersed in said hydrophilic polymer in an amount in the range of 10% to 35% by weight of the ibuprofen, said dissolution additive comprising an alkali metal salt, an amino acid having a neutral to alkaline side chain, croscarmellose or a salt thereof, or a combination of any two of such dissolution additives; and an inert formulation additive dispersed in said hydrophilic polymer in an amount in the range of 15% to 75% by weight of the ibuprofen, said formulation additive comprising microcrystalline cellulose, silica, magnesium stearate, stearic acid, lactose pre-gelatinized starch, dicalcium phosphate or a combination of any of them, wherein at least 20% of the ibuprofen is released within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter releases ibuprofen at a relatively constant rate over a period of at least 8 hours, and wherein at least 70% of the ibuprofen is released over a period of not more than 14 hours following such administration or exposure. The disclosure also relates to use of the dosage form in the preparation of medicaments for the treatment of inflammation.

Description

<div class="application article clearfix" id="description"> WO 2006/039692 554213 PCT/US2005/035630 MODIFIED RELEASE IBUPROFEN DOSAGE FORM CROSS REFERENCE TO RELATED APPLICATIONS The present invention claims the benefit of U.S. Provisional Applications Nos. 60/614,932, filed September 30, 2004 and 60/689,631, filed June 10, 2005, and 5 U.S. Non-Provisional Application No. (TO BE ASSIGNED), filed September 29, 2005. BACKGROUND OF THE INVENTION Ibuprofen is 2-(4-isobutylphenyl)propionic acid and is a non-steroidal antiinflammatory compound (NSAID), which exhibits high levels of anti-inflammatory, analgesic and antipyretic activities necessary for the effective treatment of rheumatoid 10 arthritis and osteo-arthritis and other inflammatory conditions. Most dosage forms of ibuprofen are immediate release dosage forms that provide rapid onset of therapeutic action, then rapidly declining levels of active ingredient, necessitating repeated dosing. They do not maintain therapeutic levels from one treatment over an extended period of time. Repeat dosing is thus required at intervals of four to six hours. Formulations that 15 claim extended release fail to have an initial burst of the drug and thus exhibit substantial delay between administration and the achievement of an effective therapeutic blood level. Therefore, a need exists for a solid dosage form, for example a compressed tablet, which provides an initial burst of released ibuprofen, leading to prompt onset of action, then thereafter provides a sustained release of sufficient 20 ibuprofen to maintain beneficial blood levels of ibuprofen over an extended period of 8 or more hours. SUMMARY OF THE INVENTION In accordance with the foregoing, we have provided a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of 25 ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 ng/ml over an extended period of at least 8 hours following administration of a single dose. More particularly, the invention comprises a solid dosage form for oral administration comprising a hydrophilic polymer, a pharmaceutically effective amount of 30 ibuprofen in the range of 300 mg to 800 mg uniformly dispersed in the polymer, a dissolution additive dispersed in the polymer in an amount in the range of 10% to 35% by weight of the ibuprofen, and a formulation additive dispersed in the polymer in an amount of 15% to 75% by weight of the ibuprofen. The dosage form releases ibuprofen at a rate sufficient to initially deliver a effective amount of ibuprofen within about 2.0 35 hours following administration. The dosage form then subsequently delivers the RECEIVED at IPONZ on 24 December 2009 554213 -2- remaining amount of ibuprofen at a relatively constant rate sufficient to maintain a level of ibuprofen over a predetermined delivery period of for at least 8 hours. Accordingly, in a first aspect the invention provides a solid dosage form for modified oral administration of ibuprofen comprising: 5 a solid dosage form for modified oral administration of ibuprofen comprising: a hydrophilic polymer; 300 to 800 mg of ibuprofen in the solid dosage form uniformly dispersed in said polymer; a dissolution additive dispersed in said hydrophilic polymer in an amount in the range 10 of 10% to 35% by weight of the ibuprofen, said dissolution additive comprising an alkali metal salt, an amino acid having a neutral to alkaline side chain, croscarmellose or a salt thereof, or a combination of any two of such dissolution additives; and an inert formulation additive dispersed in said hydrophilic polymer in an amount in the range of 15% to 75% by weight of the ibuprofen, said formulation additive comprising 15 miscrocystalline cellulose, silica, magnesium stearate, stearic acid, lactose, pre-gelatinized starch, dicalcium phosphate or a combination of any of them, wherein at least 20% of the ibuprofen is released within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter releases ibuprofen at a relatively constant rate over a period of at least 8 hours, and 20 wherein at least 70% of the ibuprofen is released over a period of not more than 14 hours following such administration or exposure. 2341396_1.DOC RECEIVED at IPONZ on 24 December 2009 554213 -2A- As used herein, a relative constant rate refers to a substantially linear relationship shown in the examples following the initial burst (up to about 2 hours) between percentage released and elapsed time. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1: In-vitro dissolution of Example 1 Figure 2: In-vitro dissolution of Example 2 Figure 3: In-vitro dissolution of Example 3 Figure 4: In-vitro dissolution of Example 4 Figure 5: In-vitro dissolution of Example 5 Figure 6: In-vitro dissolution of Example 6 Figure 7: In-vitro dissolution of Example 7 Figure 8: In-vitro dissolution of Example 8 Figure 9: In-vitro dissolution of Example 9 Figure 10: In-vitro dissolution of Example 10 Figure 11: In-vitro dissolution of Example 11 Figure 12: In-vitro dissolution of Example 12 Figure 13: In-vitro dissolution of Example 13 Figure 14: In-vitro dissolution of Example 14 Figure 15: In-vitro dissolution of Example 15 Figure 16: In-vitro dissolution of Example 16 Figure 17: In-vitro dissolution of Examples 17 and 18 Figure 18: In-vitro dissolution of BRUFEN RETARD, an extended release form of Ibuprofen available for sale in Europe. Figure 19: In-vivo data from comparison of present invention versus Motrin® DETAILED DESCRIPTION OF THE INVENTION The present invention is further illustrated and described by reference to the following disclosure, examples and discussion below. In the examples and discussion which follow, the use of particular polymers, electrolytes, additives, fillers and tableting aids are provided by way of example only and are not intended to limit the scope of this invention. Although the invention is illustrated and described herein with reference to specific embodiments, the invention is not intended to be limited to the details shown. Rather, various modifications may be made in the details within the scope and range of equivalents of the claims and without departing from the invention. The ibuprofen content of the dosage form may be between in the range about 300 mg and about 800 mg per dosage unit, preferably about 300, 400 or 600 mg WO 2006/039692 554213 PCT/US2005/035630 per unit dosage form. Also contemplated is using prodrugs of ibuprofen such as ibuprofen-iysine and ibuprofen-arginine. If a smaller dosage form is desired, a single dose of ibuprofen may be divided between multiple, for example two to three, dosage units, such as tablets, which may be administered at substantially the same time. The 5 dosage form may comprise from about 25% to about 75% by weight ibuprofen. The hydrophilic polymer used in the dosage form may be selected from a wide variety of hydrophilic polymers. Hydrophilic polymers suitable for use in the sustained release formulation include: one or more natural or partially or totally synthetic hydrophilic gums such as acacia, gum tragacanth, locust bean gum, guar gum, 10 or karaya gum; modified cellulosic substances such as methylcellulose, hydroxy methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethylcellulose, or carboxyethylcellulose; proteinaceous substances such as agar, pectin, carrageenan, and alginates; and other hydrophilic polymers such as carboxypolymethylene, gelatin, casein, zein, bentonite, magnesium aluminum silicate, 15 polysaccharides, modified starch derivatives, and other hydrophilic polymers known to those of skill in the art, or a combination of such polymers. These hydrophilic polymers gel and dissolve slowly in aqueous acidic media thereby allowing the ibuprofen to diffuse from the gel in the stomach and gastrointestinal tract. Hydroxypropyl methylcellulose (HPMC) and other hydrophilic 20 polymers mentioned above may be available in forms that have varying viscosity ratings. In general these polymers, or the combination of them, may be present in the dosage form alone or in combination in an amount or at a concentration in the range of 10% to 70% by weight of the ibuprofen present in the formulation, for example 15% to 50% or 15% to 33%, depending on the release pattern which is sought to be achieved with the 25 particular dosage form. One hydrophilic polymer useful in the present invention is HPMC K4M. This is a nonionic swellable hydrophilic polymer manufactured by "The Dow Chemical Company" under the tradename "Methocel." HPMC K4M is also referred to as HPMC K4MP, in which the "P" refers to premium cellulose ether designed for controlled release 30 formulations. The "4" in the abbreviation suggests that the polymer has a nominal viscosity (2% in water) of 4000. The percent of methoxyl and hydroxypropyl groups are 19-24 and 7-12, respectively. In its physical form, HPMC K4M is a free-flowing, off-white powder with a particle size limitation of 90%<100 mesh screen. A more complete list of HPMC is K100LVP, K15MP, K100MP, E4MP and E10MP CR with nominal viscosities 35 of 100, 15000, 100000, 4000, and 10000 respectively. The solid dosage form also includes at least one formulation additive such as one or more of a filler, a diluent or a compression aid. These are additives which aid WO 2006/039692 554213 PCT/US2005/035630 in preparation or manufacture of the dosage form and for a tableted solid dosage form a tableting aid such as microcrystalline cellulose (MCC), such MCC 105 (particle size of about 20 urn), MCC 200 (particle size of about 180 nm) and MCC 302 (particle size of about 90 urn), silicified microcrystalline cellulose (MCC bonded to Si02), such as 5 Prosolv90 (particle size of about 90 pm) and Prosolv50 (paricle size of about 50 urn), lactose, such as spray dried lactose (Lactopress®), dicalcium phosphate, silica or pregelatinized starch and combinations thereof may be incorporated into the formulation in an amount or at a concentration in the range of about 15% to about 75% by weight of the ibuprofen present in the dosage form. It is contemplated that various particle sizes 10 of microcrystalline cellulose may be used if desired, for example two different particle sizes in which each of them are present in individual amounts in the range of 17% to 33% by weight of the ibuprofen present in the formulation. In one embodiment, one can pre-blend silica with ibuprofen or pre-blend silica and/or formulation additive MCC with ibuprofen. 15 In addition to formulation additives, the dosage form also contains at least one dissolution additive. Such additives which generally comprise a pore-forming, wetting or disintegration agent which facilitates dissolution of the dosage form. Such dissolution additives may be present in the dosage form at an amount or concentration in the range of about 10% to about 35% by weight of the ibuprofen, for example, at 20 10% to about 15%. The additive may suitably be selected from alkali metal salts, such as sodium and potassium carbonate; sodium carbonate, monohydrate; sodium bicarbonate; amino acids with neutral-to-basic side chains, such as glycine, alanine, valine, leucine, iso-leucine, cysteine, methionine, phenylalanine, proline, lysine, arginine, histidine, serine, threonine, asparagine, tryptophan, tyrosine and glutamine; 25 conventional pharmaceutical disintegrants and combinations or mixtures thereof. Examples of such additives are sodium carbonate, glycine, arginine and croscarmellose sodium. In addition to ibuprofen, multiple active ingredients are contemplated and may be present in the present dosage form. Combinations of ibuprofen with actives 30 such as caffeine, psuedophedrine, aspirin, phenylephrine and/or sympathomemetics, analgesics, such as hydrocodone, and antihistamines are within the scope of the invention. Favorable in vitro characteristics that lead to an acceptable in vivo efficacy are contemplated as 20% or greater release within 2.0 hour after oral administration or 35 contact with an aqueous environment, followed by more gradual release over several hours, leading to release of at least 70% release in 8 to 12 hours following administration or contact with an aqueous environment. The method of determining in WO 2006/039692 554213 PCT/US2005/035630 5 - vitro release is using an agitated aqueous medium, such as stirring at 50 rpm in pH 7.2 KH2P04 media; or surrogate methods using alternate pH media, such as 0.1N HCI or SGF @ pH 1.2 for an initial (30min-2hr period or using alternate hydrodynamic conditions such as 100 to 150rpm for a period of l-2hrs). 5 The accepted range for minimal efficacy in vivo is from about 6.4 (xg/ml to about 10 ng/ml mean ibuprofen blood concentration. Examples The formulations of the invention are illustrated by the following examples. The use of particular polymers, electrolytes, additives, fillers and 10 compression aids are not intended to limit the scope of this invention but are exemplary only. The solid dosage comprising a modified release formulation of the present invention was prepared and tested for both in vitro release and in vivo blood levels as described in Examples 1-20 below. In the in vivo testing, the dissolution rates of the 15 subject dosage forms were compared against two commercially available tablets, one being an immediate release formulation of 200 mg of ibuprofen and the other being an immediate release 600 mg ibuprofen formulation. The solid dosage forms comprising the modified release formulation of the present invention demonstrated an initial burst similar to an immediate release tablet and a slower, more controlled release of ibuprofen 20 over a eight hour period, as best seen in Fig. 19. Unless otherwise noted, all in vitro release performance was evaluated in a type II dissolution apparatus in 900mL KH2P04 buffer, pH 7.2, at 50rpm paddle speed. Example 1 In one embodiment, the formulation comprised ibuprofen, hydroxypropyl 25 methylcellulose (HPMC K15M and HPMC K100LV), glycine and sodium carbonate, in which HPMC K15M was present at a concentration of 18% by weight of ibuprofen, HPMC K100LV was present at a concentration of 17% by weight of ibuprofen, glycine was present at a concentration of 2.5% by weight of ibuprofen, and sodium carbonate was present at a concentration of 17% by weight of ibuprofen within a monolithic 30 compressed tablet. The specific formulations are as follows: Ex. la mg Ibuprofen 90 grade 600 HPMC K15M 110 HPMC K100LV 100 MCC PH102 100 Ex. lb mg Ibuprofen 90 grade 600 HPMC K15M 125 HPMC K100LV 100 MCC PH102 100 WO 2006/039692 554213 PCT/US2005/035630 - 6 Na2C03, anhydrous 150 Na2C03, anhydrous 150 Glycine 15 Glycine 15 Silica, Syloid 244 20 Silica, Syloid 244 20 Mg Stearate 10 Mg Stearate 10 Total: A 1105 Total: 1120 Ingredients were passed through a 30-mesh screen and blended with the remaining formulation components in a V-blender. The resulting powder was compressed into tablets using conventional compression techniques. 10 As shown in Fig. 1, the results of this Example demonstrate that the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material, leading to in excess of 90% release in approximately 12 hours. This formulation thus overcomes one of the principle problems with many ibuprofen formulations which exhibit substantially less than complete release 15 over an extended period of time. Example 2 In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K100M and HPMC K100LV), sodium carbonate, flow agents and tableting aids, in which HPMC K100M was present at a concentration of 20 17% by weight of ibuprofen, HPMC K100LV was present at a concentration of 17% by weight of ibuprofen and sodium carbonate was present at a concentration of 25% by weight of ibuprofen within a compressed monolithic tablet. The specific formula is as follows: Ex. 2 mg Ibuprofen 600 HPMC K100M 100 HPMC K100LV 100 Na2C03, anhydrous 150 MCC PH102 150 Silica, Syloid 244 20 Mg Stearate 10 Total: 1130 25 The formulation components were mixed in a V-blender. The resulting powder was compressed into tablets using conventional technologies. In this Example a combination of a medium to high viscosity HPMC and a low viscosity HPMC was used. WO 2006/039692 554213 PCT/US2005/035630 As shown in Fig. 2, the results of this Example demonstrate an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The burst effect provides release of 20% of ibuprofen within 2 hours, and the release of approximately 90% of the available ibuprofen over a period of 5 12 to 14 hours. Example 3 In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K15M and HPMC K100LV), sodium carbonate, flow agents and tableting aids, in which HPMC K100M was present at a concentration of 17% 10 by weight of ibuprofen, HPMC K100LV was present at a concentration of 17% by weight of ibuprofen and sodium carbonate was present at a concentration of 25% by weight of ibuprofen within a compressed monolithic tablet. Ex. 3 mg Ibuprofen 600 HPMC K15M 100 HPMC K100LV 100 MCC PH102 100 Na2C03, anhydrous 150 Glycine 15 Silica, Syloid 244 20 Mg Stearate 10 Total: 1095 15 The formulation components were mixed in a V-blender. The resulting powder was compressed into tablets using conventional compression technology. In this Example a combination of a medium to high viscosity HPMC and a low viscosity HPMC was used. As shown in Fig. 3, the results of this Example demonstrate an in vitro 20 release profile comprising a burst effect providing release of 20% of ibuprofen within 2 hours, followed by the sustained release of the remaining material evidencing release of 100% of the ibuprofen present in about 11 hours and greater than 90% in approximately 8 hours. Example 4 25 In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K100M and HPMC K100LV), sodium carbonate, flow agents and tableting aids, in which HPMC K100M was present at a concentration of WO 2006/039692 554213 PCT/US2005/035630 - 8 - 17% by weight of ibuprofen, HPMC K100LV was present at a concentration of 17% by weight of ibuprofen, and sodium carbonate was present at a concentration of 25% by weight of ibuprofen within a compressed monolithic tablet. Ex. 4 mg Ibuprofen 600 HPMC K100M 100 HPMC K100LV 100 MCC PH102 100 Na2CO3, anhydrous 150 Silica, Syloid 244 20 Mg Stearate 10 Total: 1080 5 The formulation components were mixed in a V-blender. The resulting powder was compressed into tablets using conventional technologies. In this Example a combination of a medium to high viscosity HPMC and a low viscosity HPMC was used. As shown in Fig. 4, the results of this Example demonstrate an in vitro 10 release profile comprising a burst effect, followed by the sustained release of the remaining material. 20% of ibuprofen was released within 2 hours, followed by gradual sustained release, resulting in approximately 95% release after 12 hours. Example 5 In another embodiment, the formulation comprised ibuprofen, 15 hydroxypropyl methylcellulose (HPMC K100M), polyethylene oxide (PEO WSRN 301), sodium carbonate, glycine, flow agents and tableting aids, in which HPMC was present at a concentration of 33% by weight of ibuprofen, glycine was present at a concentration of 8.25% by weight of ibuprofen and sodium carbonate was present at a concentration of 25% by weight of ibuprofen within a compressed monolithic tablet. Ex. 5 mg Ibuprofen 600 PEO 301 50 HPMC K100M 100 MCC PH102 100 Na2C03, anhydrous 150 Glycine 20 Silica, Syloid 244 20 WO 2006/039692 554213 PCT/US2005/035630 Mg Stearate 10 Total: 1050 The formulation components were mixed in a V-blender. The resulting powder was compressed into tablets using conventional compression technology. As shown in Fig. 5, the results of this Example demonstrate an in vitro 5 release profile comprising a burst effect, followed by the sustained release of the remaining material. For this formulation 20% of ibuprofen was released within 2 hours, but incomplete release was evidenced after 12 hours. Example 6 In another embodiment, the formulation comprised ibuprofen, 10 hydroxypropyl methylcellulose (HPMC K15M), potassium carbonate, flow agents and tableting aids, in which HPMC was present at a concentration of 33% by weight of ibuprofen, and potassium carbonate was present at a concentration of 17% by weight of ibuprofen within a compressed monolithic tablet. Ex. 6 mg Ibuprofen 90 grade 600 MCC PH 105 210 HPMC K15M Prem 190 MCC PH 200 100 K2C03 anhydrous 100 1200 15 The formulation components were mixed in a V-blender. The resulting powder was compressed into tablets using conventional compression technology. As shown in Fig. 6, the results of this Example demonstrate an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. 20% of ibuprofen was released in under 2 hours, and release was 20 thereafter sustained over a period of 15 hours. However, incomplete release was exhibited by the dosage form. Example 7 In this embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K15M), sodium carbonate, microcrystalline cellulose (MCC PH105 25 and MCC PH200), in which HPMC was present at a concentration of 33% by weight of ibuprofen, sodium carbonate was present at a concentration of 17% by weight of ibuprofen, MCC PH105 was present at a concentration of 33%, and MCC PH200 was present at a concentration of 17% within a compressed monolithic tablet. WO 2006/039692 554213 PCT/US2005/035630 - 10 - Ex. 7 Mg Ibuprofen 90 grade 600 HPMC K15M Prem 190 MCC PH 105 210 MCC PH 200 100 ISIa2C03 anhydrous 100 1200 All ingredients were passed through a 30-mesh screen. The ibuprofen and the MCC 105 were blended in a V-blender. The resulting homogenous pre-blend was granulated with water, dried and subsequently blended with the remaining formulation 5 components in a V-blender. The resulting powder was compressed into tablets using conventional compression technology. As shown in Fig. 7, this Example demonstrates an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The burst effect releases 20% of ibuprofen in under 2 hour, followed by relatively 10 constant release over the next 10 -12 hours and resulting in approximately 90% release after 12 hours. Example 8 In the embodiment of Example 1, the tablet resulting from the formulation was split into two equal parts, and both sections were placed into a dissolution vessel. Ex. 8 mg Ibuprofen 90 grade 600 HPMC K15M 110 HPMC K100LV 100 MCC PH102 100 Na2C03, anhydrous 150 Glycine 15 Silica, Syloid 244 20 Mg Stearate 10 Total: 1105 15 As shown in Fig. 8, the results of this Example demonstrates an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material, even when split into sections after tableting. In each case 20% of WO 2006/039692 554213 PCT/US2005/035630 - 11 - ibuprofen was released in less than one hour and substantially all the ibuprofen had been released at about 12 hours. Example 9 In one embodiment, the formulation comprised ibuprofen, hydroxypropyl 5 methylcellulose (HPMC K15M), sodium carbonate, microcrystalline cellulose (MCC PH 302), in which HPMC was present at a concentration of 33% by weight of ibuprofen, sodium carbonate was present at a concentration of 18% by weight of ibuprofen, and MCC PH 302 was present at a concentration of 33% within a compressed monolithic tablet. Ex. 9 mg Ibuprofen 90 grade 300 HPMC K15M Prem 100 MCC PH 302 100 l\la2C03 anhydrous 50 Glycine 7.5 Silica 5.5 Total: 563 10 All ingredients were passed through a 30-mesh screen and blended in a V-blender. The resulting homogenous pre-blend was granulated with water, dried and subsequently blended with the remaining formulation components in a V-blender. The resulting powder was compressed into tablets using conventional technologies. 15 As shown in Fig. 9, the results of this Example demonstrate an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. 20% of ibuprofen was released within 2 hours, about 90% release was obtained in about 9 hours followed by 100% release in under 16 hours. Example 10 20 In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K4M), flow agents and tableting aids, in which HPMC K4M was present at a concentration of 32% by weight of ibuprofen, and arginine was present at a concentration of 17% by weight of ibuprofen within a compressed monolithic tablet. Ex. 10 mg Ibuprofen 90 grade 600 Silica 5.5 MCC PH 105 210 WO 2006/039692 554213 PCT/US2005/035630 - 12 - HPMC K4M Prem 190 Arginine 100 Silica 5.5 Total: 1111 The formulation components were mixed in a V-blender. The resulting powder was compressed into tablets using conventional technologies. As shown in Fig. 10, the results of this Example demonstrate an in vitro 5 release profile comprising a slight burst effect, followed by the sustained release of the remaining material. While the burst effect in this formulation produces somewhat delayed achievement of the percentage released, this formulation demonstrates in excess of 90% release over a period of 8 hours. Example 11 10 In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K4M), sodium carbonate, arginine, flow agents and tableting aids, in which HPMC K4M was present at a concentration of 32% by weight of ibuprofen, sodium carbonate was present at concentration of 17% by weight of the ibuprofen, and arginine was present at a concentration of 17% by weight of ibuprofen 15 within a compressed monolithic tablet. Ex. 11 mg Ibuprofen 90 grade 600 Silica 5.5 MCC PH 105 210 HPMC K4M Prem 190 Na2C03 anhydrous 100 MCC PH 200 100 Arginine 100 Silica 5.5 Stearic Acid 12 Total: 1323 The formulation components are mixed in a V-blender. The resulting powder was compressed into tablets using conventional technologies. 20 As shown in Fig. 11, the results of this Example demonstrate the in vitro release profile comprising a burst effect, followed by the sustained release of the WO 2006/039692 554213 PCT/US2005/035630 - 14 - components in a V-blender. The resulting powder was compressed into tablets using conventional technologies. As shown in Fig. 12, the results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by 5 the sustained release of the remaining material, with little or no alteration in release profile when the tableting aid selection is varied. The in vitro profile shows greater than 20 % release before 2.0 hours with a constant rate release and at least 70% release by 14 hours. Example 13 10 In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K4M), microcrystalline cellulose (MCC 105), sodium carbonate, flow agents and various tableting aids, in which HPMC K4M was present at a concentration of 32% by weight of ibuprofen, sodium carbonate was present at . concentration of 17% by weight of the ibuprofen, and croscarmellose sodium was 15 present at a concentration of 3% by weight of ibuprofen within a monolithic tablet. Ex. 13 mg Ibuprofen 90 grade 600 Silica 5.5 MCC PH 105 210 HPMC K4M Prem 190 Na2C03 anhydrous 100 MCC PH 200 100 Croscarmellose sodium 18 Silica 5.5 Stearic acid ~ 1% 12 Total: 1241 All ingredients were passed through a 30-mesh screen. The ibuprofen, silica and the MCC 105 were blended in a V-blender. The resulting homogenous pre-20 blend was granulated with water, dried and subsequently blended with the remaining formulation components in a V-blender. The resulting powder was compressed into tablets using conventional technologies. As shown in Fig. 13, the results of this Example demonstrates an in vitro release profile comprising a burst effect, followed by the sustained release of the 25 remaining material. The in vitro profile shows greater than 20% release before 2.0 WO 2006/039692 554213 PCT/US2005/035630 hours followed by a relatively constant rate release and at least 80% release by 14 hours. Example 14 In another embodiment, the formulation comprised ibuprofen, 5 hydroxypropyl methylcellulose (HPMC K4M), microcrystalline cellulose (MCC 105), glycine, sodium carbonate, flow agents and various tableting aids, in which HPMC K4M was present at a concentration of 32% by weight of ibuprofen, sodium carbonate was present at concentration of 17% by weight of the ibuprofen, glycine was present at a concentration of 8% by weight of ibuprofen and croscarmellose sodium was present at a 10 concentration of 6% by weight of ibuprofen within a monolithic tablet. Ex. 14 mg Ibuprofen 90 grade 600 MCC PH 105 200 Silica 5.5 HPMC K4M Prem 190 MCC PH 200 100 Glycine 50 Croscarmellose sodium 35 Silica 5.5 Stearic acid ~ 1% 12 Total: 1198 All ingredients were passed through a 30-mesh screen. The ibuprofen, silica and the MCC 105 were blended in a V-blender. The resulting homogenous pre-15 blend was granulated with water, dried and subsequently blended with the remaining formulation components in a V-blender. The resulting powder was compressed into tablets using conventional technologies. As shown in Fig. 14, the results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by 20 the sustained release of the remaining material. The in vitro profile shows greater than 20% release before 2.0 hours with a constant rate release and at least 70% release by 14 hours. Example 15 In another embodiment, the formulation comprised ibuprofen, 25 polyethylene oxide (PEO 301), PEO 60K, glycine, sodium carbonate, flow agents and various tableting aids, in which PEO was present at a concentration of 32% by weight of WO 2006/039692 554213 PCT/US2005/035630 - 16 - ibuprofen, sodium carbonate was present at concentration of 25% by weight of the ibuprofen, and glycine was present at a concentration of 37% by weight of ibuprofen within a monolithic tablet. Ex. 15 mg Ibuprofen 400 PEO 301 50 PEO 60K 75 Na2C03 100 Glycine 150 Maltodextrin M-580 100 Stearic acid 10 Silica 10 Total: 895 5 All ingredients were passed through a 30-mesh screen. The ibuprofen was blended with the formulation components in a V-blender. The resulting powder was compressed into tablets using conventional technologies. As shown in Fig. 15, the results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by 10 the sustained release of the remaining material. The in vitro profile shows greater than 20% release before 2.0 hours with a constant rate release and at least 80% release by 8 hours. Example 16 In another embodiment, the formulation comprised ibuprofen, 15 polyethylene oxide (PEO 301), PEO 60K, glycine, sodium carbonate, flow agents and various tableting aids, in which PEO was present at a concentration of 32% by weight of ibuprofen, sodium carbonate was present at concentration of 25% by weight of the ibuprofen, and glycine was present at a concentration of 37% by weight of ibuprofen within a monolithic tablet. Ex. 16 mg Ibuprofen 400 PEO 301 50 PEO 60K 50 Na2C03 100 Glycine 100 Maltodextrin M-580 100 WO 2006/039692 554213 PCT/US2005/035630 - 13 - remaining material. The initial release is greater than 20% of ibuprofen in less than two hours, and approximately 90% release over a period of 14 hours. Example 12 In another embodiment, the formulation comprised ibuprofen, 5 hydroxypropyl methylcellulose (HPMC K4M), microcrystalline cellulose (MCC 105), sodium carbonate, flow agents and various tableting aids, in which HPMC K4M was present at a concentration of 32% by weight of ibuprofen, sodium carbonate was present at concentration of 17% by weight of the ibuprofen, and tableting aid, either Lactopress (12a), dicalcium phosphate (12b), or pregelatinized starch (12c), was present at a 10 concentration of 17% by weight of ibuprofen within a monolithic tablet. 15 Ex. 12a mg Ibuprofen 90 grade 600 Silica 5.5 MCC PH 105 210 HPMC K4M Prem 190 Na2C03 anhydrous 100 Lactopress 100 Silica 5.5 Stearic acid 12 Total: 1223 Ex. 12c mg Ibuprofen 90 grade 600 Silica 5.5 MCC PH 105 210 HPMC K4M Prem 190 Na2C03 anhydrous 100 Starch 1500 100 Silica 5.5 Stearic acid 12 Total: 1223 Ex. 12b mg Ibuprofen 90 grade 600 Silica 5.5 MCC PH 105 210 HPMC K4M Prem 190 Na2C03 anhydrous 100 Dicalcium phosphate 100 Silica 5.5 Stearic acid 12 Total: 1223 All ingredients were passed through a 30-mesh screen. The ibuprofen and the MCC 105 were blended in a V-blender, The resulting homogenous pre-blend was granulated with water, dried and subsequently blended with the remaining formulation WO 2006/039692 554213 PCT/US2005/035630 - 17 - Stearic acid 10 Silica 10 Total: 820 All ingredients were passed through a 30-mesh screen. The ibuprofen was blended with the formulation components in a V-blender. The resulting powder was compressed into tablets using conventional technologies. As shown in Fig. 16, the results of this Example demonstrate the 5 invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The in vitro profile shows greater than 20 % release before 2.0 hours with a constant rate release and at least 90% release by 8 hours. Example 17 10 In another embodiment, the formulation comprised ibuprofen, polyethylene oxide (PEO 301), glycine, sodium carbonate, flow agents and various tableting aids, in which PEO was present at a concentration of 25% by weight of ibuprofen, sodium carbonate was present at concentration of 25% by weight of the ibuprofen, and glycine was present at a concentration of 25% by weight of ibuprofen 15 within a monolithic tablet. Ex. 17 mg Ibuprofen 400 PEO 301 100 Na2C03 100 Glycine 100 Stearic acid 10 Total: 710 All ingredients were passed through a 30-mesh screen. The ibuprofen was blended with the formulation components in a V-blender. The resulting powder was 20 compressed into tablets using conventional technologies. As shown in Fig. 17, the results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The in vitro profile shows greater than 20 % release before 2.0 hours with a constant rate release and at least 80% release by 25 8 hours. WO 2006/039692 554213 PCT/US2005/035630 - 18 -Example 18 In another embodiment, the formulation comprised ibuprofen, polyethylene oxide (PEO 301), glycine, sodium carbonate, croscarmellose sodium, flow agents and various tableting aids, in which PEO was present at a concentration of 25% 5 by weight of ibuprofen, sodium carbonate was present at concentration of 25% by weight of the ibuprofen, and glycine was present at a concentration of 25% by weight of ibuprofen within a monolithic tablet. Ex. 18 mg Ibuprofen 400 PEO 301 100 Na2C03 100 Glycine 100 Croscarmellose Sodium 50 DCP 150 Stearic acid 10 Total: 910 10 All ingredients were passed through a 30-mesh screen. The ibuprofen was blended with the formulation components in a V-blender. The resulting powder was compressed into tablets using conventional technologies. As shown in Fig. 17, the results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by 15 the sustained release of the remaining material. The in vitro profile shows greater than 20% release before 2.0 hours with a constant rate release and at least 90% release by 8 hours. Comparative in vitro data 20 BRUFEN RETARD is a commercially available in Europe as a sustained release formulation of ibuprofen. BRUFEN RETARD tablets are specially formulated to allow the gradual release of active substance giving stable levels and a prolonged duration of effect over the dosage interval. BRUFEN RETARD is a film coated tablet with 800mg of ibuprofen. BRUFEN RETARD is indicated for its analgesic and anti-25 inflammatory effect in the treatment of rheumatoid arthritis (including juvenile rheumatoid arthritis or Still's disease), ankylosing spondylitis, and osteo-arthritis. BRUFEN RETARD is indicated in the treatment of non-articular rheumatism including WO 2006/039692 554213 PCT/US2005/035630 - 19 - fibrositis. BRUFEN RETARD is indicated in periarticular conditions such as frozen shoulder (capsulitis), bursitis, tendinitis, tenosynovitis and low-back pain. BRUFEN RETARD can also be used in soft-tissue injuries such as sprains and strains. BRUFEN RETARD is also indicated for its analgesic effect in the relief of mild to moderate pain such as 5 dysmenorrhoea, dental, post-episiotomy pain and post-partum pain. Example 19 fFiaure 181 BRUFEN RETARD tablet in vitro release performance was evaluated in a type II dissolution apparatus in 900mL KH2P04 buffer, pH 7.2, at 50rpm paddle speed. As shown in Fig. 18, the results of this Example demonstrate the in vitro 10 data results of BRUFEN RETARD. The figure shows that BRUFEN RETARD is incapable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. BRUFEN RETARD fails to deliver to release at least 20% of ibuprofen by 2.0 hours with a constant rate of release with at least 70% release at 14 hours. 15 Example 20 - In Vivo Trial In the in vivo testing, serum concentrations of subjects taking tablets comprising the modified release formulation of the present invention were compared with serum concentrations of subjects taking immediate release ibuprofen tablets 20 (Motrin® IB 200 mg and Motrin® 600 mg). Tablets comprising the modified release formulation of the present invention demonstrated a burst effect followed by sustained release and therapeutic concentration at extended time periods that the other two immediate release formulations did not. The minimum mean serum plasma ibuprofen concentration in the blood of the subject was between 8 and 10|ig/ml for Motrin® IB.. 25 The in vivo behavior of modified release solid dosages of la and lb from Example 1 were compared to the in vivo behavior of an immediate release formulation (MOTRIN®). The open-label study involved 10 healthy male volunteers over the age of 18. Following an overnight fast of at least ten hours, each subject received either one 600 mg dose of one of the two above described modified release tablets or 200 mg 30 every four hours for 3 doses of the immediate release formulation of MOTRIN® IB or one 600 mg tablet of MOTRIN®. 88 blood samples were taken prior to dosing and at specific intervals up to 12 hours after dosing. The blood samples were kept in ice bath prior to centrifugation and were centrifuge as soon as possible under refrigerated condition at 35000 rpm for seven 35 minutes. The collected plasma from each blood collection tube was aliquotted into pre-cooled labeled polypropylene tubes. The samples were kept in an ice bath, then stored frozen at minus 25 °C ±10 °C until assayed. WO 2006/039692 554213 PCT/US2005/035630 - 20 - The plasma samples were analyzed by a fully validated HPLC method. The analytes were separated by reverse phase chromatography. Evaluation of the assay was carried out by the construction of an eight point calibration curve (excluding zero concentration) covering the range of 0.400 jig/ml to 51.200 ng/ml (in human plasma) for 5 ibuprofen. The slope and intercept of the calibration curves were determined through weighted linear regression analysis (1/conc.2). The results are depicted in FIGURE 19. Table 1. Summary of 90% CI Formulation Reference: D (1 x 600 mg) Reference: E (3 x 200 mg) Cmax AUCo-iast AUC0.m Cmax AUCo-last AUC0-„ B (la) 42.4-53.8 96.2-115 97.0-116 67.0-85.0 86.9-104 86.3-103 C (lb) 44.7-57.0 96.9-116 98.7-119 70.7-90.3 87.5-105 87.7-106 D - - - 140-179 82.3-99.2 80.9-97.7 E 55.9-71.5 101-122 102-124 - - - D is a 3 x 200mg MOTRIN® IB 10 E is a 1 x 600mg MOTRIN® Treatments (B & C) versus Treatment E The systematic exposure to ibuprofen after the administration of the one 600 mg ibuprofen tablet la or lb (Treatments B & C) was similar to that obtained when compared to the administration of one MOTRIN® 600mg tablet. The peak exposure to 15 ibuprofen from one 600 mg ibuprofen tablet la or lb (Treatments A-C) was significantly lower than that from the MOTRIN® 600mg tablet. The absorption time was modified comparing one 600 mg ibuprofen tablet la or lb (Treatments B & C) with median Tmax value of 5.Oh to a 1.5h Tmax of one MOTRIN® 600mg tablet. Treatments (B & C) versus Treatment D 20 The systematic exposure to ibuprofen after the administration of the one 600 mg ibuprofen tablet la or lb (Treatments B & C) was similar to that obtained when compared to the administration, of three MOTRIN® IB 200mg tablets. The peak exposure to ibuprofen from one 600 mg ibuprofen tablet la or lb (Treatments B & C) was significantly lower than that from three MOTRIN® IB 200mg tablets. The absorption time 25 was modified comparing one 600 mg ibuprofen tablet la or lb (Treatments B & C) with median Tmax value of 5.Oh to a l.Oh Tmax of three MOTRIN® IB 200mg tablet. WO 2006/039692 554213 PCT/US2005/035630 - 21 - Figure 19 depicts the results discussed above. Treatment D shows an initial burst that falls to a valley at four hours and the second tablet is administered. This valley again happens at the eighth hour. This valley constitutes the minimum plasma concentration for ibuprofen to be considered therapeutic. A mean ibuprofen 5 plasma concentration of about 6.4-10 ng/ml is considered the concentration of ibuprofen needed in the blood to be considered clinically effective. Treatment E shows an extreme initial burst of ibuprofen followed by a steady decline that falls below therapeutic threshold at about 6 hours. Treatments B and C have an initial burst of ibuprofen that reaches the level 10 of 6.4 ng/ml at about 0.5 to 1 hour and maintains the level until about hour 12. The present invention provides for a single dosage of ibuprofen that provides an initial burst similar to an immediate release formulation of ibuprofen and then provides a mean ibuprofen plasma concentration of above 6.4 ng/ml for about 12 hours. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 1 2 1 2 1 2 1 2 3 4 1 2 1 2 3 1 2 3 4 WO 2006/039692 554213 PCT/US2005/035630 - 22 - </div>

Claims

<div class="application article clearfix printTableText" id="claims"> What is Claimed:

1. A solid dosage form for modified oral administration of ibuprofen comprising: a hydrophilic polymer; 300 to 800 mg of ibuprofen in the solid dosage form uniformly dispersed in said polymer; a dissolution additive dispersed in said hydrophilic polymer in an amount in the range of 10% to 35% by weight of the ibuprofen, said dissolution additive comprising an alkali metal salt, an amino acid having a neutral to alkaline side chain, croscarmellose or a salt thereof, or a combination of any two of such dissolution additives; and an inert formulation additive dispersed in said hydrophilic polymer in an amount in the range of 15% to 75% by weight of the ibuprofen, said formulation additive comprising microcrystalline cellulose, silica, magnesium stearate, stearic acid, lactose, pre-gelatinized starch, dicalcium phosphate or a combination of any of them, wherein at least 20% of the ibuprofen is released within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter releases ibuprofen at a relatively constant rate over a period of at least 8 hours, and wherein at least 70% of the ibuprofen is released over a period of not more than 14 hours following such administration or exposure.

2. The solid dosage form of claim 1, wherein ibuprofen is present in each dosage form in an amount of about 300 mg, 400 mg or 600 mg.

3. The solid dosage form of claim 1, wherein said polymer comprises polyethylene oxide, hydroxypropyl methylcellulose or a combination thereof.

4. The solid dosage form of claim 1, wherein said polymer comprises hydroxypropyl methylcellulose with a viscosity of at least 100 cps.

5. The solid dosage form of claim 4, wherein said hydrophilic polymer comprises a first hydroxypropyl methylcellulose having a viscosity of greater than 100 cps and a second HPMC having a viscosity of about 100 cps, each at a concentration of 17% to 42% by weight of ibuprofen.

6. The solid dosage form of claim 1, wherein said dissolution additive is sodium carbonate, glycine, arginine, croscarmellose sodium or a combination thereof.

7. The solid dosage form of claim 1, where said inert formulation additive comprises microcrystalline cellulose present at a concentration at 17% to about 33% by weight of the ibuprofen.

8. The solid dosage form of claim 7, wherein said inert formulation additive comprises a first microcrystalline cellulose having particle size of about 20 urn and a second MCC having a particles size of about 180 ^m, each of which is present at a concentration at 17% to about 33% by weight of the ibuprofen. 1 2 3 4 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 1 WO 2006/039692 554213 PCT/US2005/035630 - 23 -

9. The solid dosage form of claim 1, wherein said solid dosage form demonstrates a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 |ig/ml within two hours of administration, and wherein said solid dosage form also demonstrates a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 ng/ml for at least 8 hours after administration.

10. A modified release tablet, comprising: ibuprofen in an amount in the range of 300 mg to 800 mg per tablet; a hydrophilic polymer; a dissolution additive at a concentration of from 10% to 35% by weight of the ibuprofen comprising alkali metal salts, an amino acid possessing neutral-to-alkaline side chain, croscarmellose or a salt thereof or a combination thereof; and an inert formulation additive comprising microcrystalline cellulose, silicified microcrystalline cellulose, dicalcium phosphate, lactose, pre-gelatinized starch or mixtures thereof, said inert formulation additive being present in said dosage in an amount of 15% to about 75% by weight of the ibuprofen, wherein said tablet demonstrates a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 (ig/ml within two hours of administration, and wherein said tablet also demonstrates a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 (ig/ml for at least 8 hours after administration.

11. The tablet of claim 10, wherein the hydrophilic polymer comprises hydroxypropyl methylcellulose at a concentration of 17% to 42% by weight of ibuprofen; wherein ibuprofen is present in an amount of about 600 mg and dispersed uniformly in said polymer; wherein said dissolution additive is sodium carbonate uniformly dispersed in said polymer; and wherein said formulation additive is two differing particle sizes of microcrystalline cellulose dispersed in said polymer, each at 15% to 50% by weight of the ibuprofen.

12. The tablet of claim 10, wherein the hydrophilic polymer comprises hydroxypropyl methylcellulose at a concentration of 17% to 42% by weight of ibuprofen; wherein ibuprofen is present in an amount of about 600 mg and is dispersed uniformly in said polymer; wherein said dissolution additive is glycine uniformly dispersed in said polymer at a concentration of 10% to 15% by weight of the ibuprofen.

13. The tablet of claim 10, 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 WO 2006/039692 554213 PCT/US2005/035630 - 24 - wherein the hydrophilic polymer comprises hydroxypropyl methylcellulose at a concentration of 17% to 42% by weight of ibuprofen; wherein ibuprofen is present in an amount of about 600 mg and is dispersed uniformly in said polymer; wherein said dissolution additive is glycine uniformly dispersed in said polymer at a concentration of 10% to 15% by weight of the ibuprofen; wherein said formulation additive is two differing particle sizes of microcrystalline cellulose dispersed in said polymer, each at 15% to 50% by weight of the ibuprofen.

14. The tablet of claim 10, wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, each at a concentration of 17% to 42% by weight of ibuprofen; wherein the dissolution additive is glycine uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen; wherein the formulation additive is two differing particle sizes of microcrystalline cellulose dispersed in said polymer, each at 15% to 50% by weight of the ibuprofen.

15. The tablet of claim 10, wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, each at a concentration of 17% to 42% by weight of ibuprofen; wherein 300mg to 800mg ibuprofen dispersed uniformly in said polymer; wherein the dissolution additive is glycine uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen and croscarmellose sodium uniformly dispersed in said polymer at a concentration of 1% to 15% by weight of the ibuprofen.

16. The tablet of claim 10, wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, each at a concentration of 17% to 42% by weight of ibuprofen; wherein 300mg to 800mg ibuprofen dispersed uniformly in said polymer; wherein the dissolution additive is glycine uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen and croscarmellose sodium uniformly dispersed in said polymer at a concentration of 1% to 15% by weight of the ibuprofen; 11 12 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 13 WO 2006/039692 554213 PCT/US2005/035630 - 25 - wherein the formulation additive is two differing particle sizes of microcrystalline cellulose dispersed in said polymer, each at 15% to 50% by weight of the ibuprofen.

17. The tablet of claim 10, wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, each at a concentration of 17% to 42% by weight of ibuprofen; wherein 300mg to 800mg ibuprofen dispersed uniformly in said polymer; wherein the dissolution additive is sodium carbonate uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen; wherein the formulation additive is two differing particle sizes of microcrystalline cellulose dispersed in said polymer, each at 15% to 50% by weight of the ibuprofen.

18. The tablet of claim 10, wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, each at a concentration of 17% to 42% by weight of ibuprofen; wherein 300mg to 800mg ibuprofen dispersed uniformly in said polymer; wherein the dissolution additive is sodium carbonate uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen, and croscarmellose sodium uniformly dispersed in said polymer at a concentration of 1% to 15% by weight of the ibuprofen; wherein the formulation additive is two differing particle sizes of microcrystalline cellulose dispersed in said polymer, each at 15% to 50% by weight of the ibuprofen.

19. The tablet of claim 10, wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, each at a concentration of 17% to 42% by weight of ibuprofen; wherein 300mg to 800mg ibuprofen dispersed uniformly in said polymer; wherein the dissolution additives are sodium carbonate uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen, glycine uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen, and croscarmellose sodium uniformly dispersed in said polymer at a concentration of 1% to 15% by weight of the ibuprofen; wherein the formulation additive is two differing particle sizes of microcrystalline cellulose dispersed in said polymer, each at 15% to 50% by weight of the ibuprofen. 1 2 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 1 2 3 4 5 6 7 8 9 10 11 12 13 1 2 3 RECEIVED at IPONZ on 24 December 2009 554213 WO 2006/039692 PCT/US2005/035630 ' - 26 -

20. The use of dosage form of claim 1 for the preparation of a medicament for treating inflammation, wherein the medicament is formulated to maintain a mean plasma ibuprofen concentration of at least 6.4 jjg/ml over a time period of 2 to 8 hours in a patient upon administration of a single dosage of the dosage form.

21. The use, in the preparation of a medicament for treating inflammation, of a modified release tablet comprising: ibuprofen in art amount in the range of 300 mg to 800 mg per tablet; a hydrophilic polymer; a dissolution additive at a concentration of from 10% to 35% by weight of the ibuprofen comprising alkali metal salts, an amino acid possessing neutral-to-alkaline side chain, croscarmellose or a salt thereof or a combination thereof; and an inert formulation additive comprising microcrystalline cellulose, siiicified microcrystalline cellulose, dicalcium phosphate, lactose, pre-gelatinized starch or mixtures thereof, said inert formulation additive being present in said dosage in an amount of 15% to about 75% by weight of the ibuprofen, wherein said tablet is formulated to demonstrate a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 pg/nil within two hours of administration, and to also demonstrate a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 pg/ml for at least 8 hours after administration, upon administration of a single dose of the tablet.

22. The use according to claim 21, wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, each at a concentration of 17% to 42% by weight of ibuprofen; wherein 300mg to 800mg ibuprofen dispersed uniformly in said polymer; wherein the dissolution additives are sodium carbonate uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen, glycine uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen, and croscarmellose sodium uniformly dispersed in said polymer at a concentration of 1% to 15% by weight of the ibuprofen; wherein the formulation additive is two differing particle sizes of microcrystalline cellulose dispersed in said polymer, each at 15% to 50% by weight of the ibuprofen.

23. The use according to claim 21, wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 RECEIVED at IPONZ on 24 December 2009 554213 WO 2006/039692 PCTYUS2005/035630 - 27 - 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, each at a concentration of 17% to 42% by weight of ibuprofen; wherein 300mg to 800mg ibuprofen dispersed uniformly in said polymer; wherein the dissolution additive is sodium carbonate uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen, and croscarmellose sodium uniformly dispersed in said polymer at a concentration of 1% to 15% by weight of the ibuprofen; wherein the formulation additive is two differing particle sizes of microcrystalline cellulose dispersed in said polymer, each at 15% to 50% by weight of the ibuprofen.

24. The use according to claim 21, wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, each at a concentration of 17% to 42% by weight of ibuprofen; wherein 600mg ibuprofen is dispersed uniformly in said polymer; and wherein the dissolution additive is sodium carbonate uniformly dispersed in said polymer at a concentration of 10% to 35% by weight of the ibuprofen, and glycine uniformly dispersed in said polymer at a concentration of 1% to 15% by weight of the ibuprofen.

25. A solid dosage form according to claim 1 substantially as herein described with reference to any example thereof.

26. A modified release tablet according to claim 10 substantially as herein descried with reference to any example thereof. </div>